Susana Banerjee

Susana Banerjee at the Royal Marsden Hospital is a leading clinician-researcher in ovarian and gynecologic cancers with expertise in platinum-resistant disease management. She was a senior investigator on the ICON8 trial evaluating weekly paclitaxel dosing and has contributed to PARP inhibitor combination studies. Her research addresses toxicity management, patient-reported outcomes, and novel combination regimens for recurrent ovarian cancer. She leads the UK Gynecological Oncology Trials Group (UKGOTG) and is an ESGO board member.